Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accounts Payables (2019 - 2025)

Historic Accounts Payables for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $6.9 million.

  • 4D Molecular Therapeutics' Accounts Payables rose 13471.27% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 13471.27%. This contributed to the annual value of $4.4 million for FY2024, which is 2477.95% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Accounts Payables stood at $6.9 million for Q3 2025, which was up 13471.27% from $8.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Accounts Payables' 5-year high stood at $8.7 million during Q2 2025, with a 5-year trough of $1.3 million in Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $3.5 million (2023), whereas its average is $3.8 million.
  • In the last 5 years, 4D Molecular Therapeutics' Accounts Payables tumbled by 6014.0% in 2022 and then soared by 21844.59% in 2023.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Accounts Payables stood at $4.8 million in 2021, then crashed by 30.27% to $3.3 million in 2022, then rose by 5.81% to $3.5 million in 2023, then rose by 24.78% to $4.4 million in 2024, then skyrocketed by 56.48% to $6.9 million in 2025.
  • Its Accounts Payables was $6.9 million in Q3 2025, compared to $8.7 million in Q2 2025 and $4.2 million in Q1 2025.